CSPG4 and neoplasm: To focus on the early pharmacokinetics of IgE, we repeated the experiments in non-tumor-bearing mice with an imaging protocol refined by adding several early time points, allowing us to determine that anti-CSPG4 IgE had in fact an initial blood half-life of less than 10 min, which is much shorter than previously reported.